Earendil Labs applies AI across discovery, design, optimization, and development to generate and progress protein-based biologics programs. Its AI-native platform has produced more than 40 programs and includes HXN-1001, a half-life extended anti-TL1A antibody that the company says is ready for Phase 2 clinical development, with multiple IND submissions planned in 2026 and 2027. The company works through a combination of internal pipeline development and strategic partnerships, including a 2025 worldwide exclusive license agreement and broader strategic collaboration with Sanofi covering multiple programs. Earendil operates alongside affiliate Helixon Therapeutics and targets therapies for autoimmune diseases, cancer, and other areas of unmet medical need. With the announced $787 million financing, the company plans to scale its AI-driven R&D organization, expand scientific and engineering teams, and advance multiple internal programs toward clinical milestones.

Total raised

$787M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2026